Brian Guan-Chyun Liu net worth and biography

Brian Liu Biography and Net Worth

Director of CG Oncology

Brian Liu, M.D. has served as a member of our board of directors since September 2022. Dr. Liu is a Managing Director at Longitude Capital, a healthcare venture capital firm, where he has been employed since 2018. Prior to joining Longitude Capital, Dr. Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey & Company from January 2016 to July 2018. Dr. Liu currently serves on the board of directors of Lassen Therapeutics and as a board observer at Quanta Therapeutics., Rivus Pharmaceuticals and Zenas BioPharma. Dr. Liu previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche Holding), Dascena Lab, Talaris Therapeutics, and Vera Therapeutics. Dr. Liu holds an M.D. from Stanford School of Medicine and a B.S. in Biomedical Engineering from Johns Hopkins University. Dr. Liu’s investment experience in the pharmaceutical industry and prior board experience contributed to our board of directors’ conclusion that he should serve as a director of our company.

What is Brian Guan-Chyun Liu's net worth?: The estimated net worth of Brian Guan-Chyun Liu is at least $65.61 million as of September 11th, 2025. Liu owns 1,515,151 shares of CG Oncology stock worth more than $65,606,038 as of December 8th. This net worth estimate does not reflect any other investments that Liu may own. Learn More about Brian Guan-Chyun Liu's net worth.
How do I contact Brian Guan-Chyun Liu?: The corporate mailing address for Liu and other CG Oncology executives is 400 SPECTRUM CENTER DRIVE SUITE 2040, IRVINE CA, 92618. CG Oncology can also be reached via phone at 949-419-6203 and via email at [email protected]. Learn More on Brian Guan-Chyun Liu's contact information.
Has Brian Guan-Chyun Liu been buying or selling shares of CG Oncology?: Brian Guan-Chyun Liu has not been actively trading shares of CG Oncology during the last quarter. Most recently, on Thursday, September 11th, Brian Guan-Chyun Liu bought 1,515,151 shares of CG Oncology stock. The stock was acquired at an average cost of $33.00 per share, with a total value of $49,999,983.00. Following the completion of the transaction, the director now directly owns 1,515,151 shares of the company's stock, valued at $49,999,983. Learn More on Brian Guan-Chyun Liu's trading history.
Who are CG Oncology's active insiders?: CG Oncology's insider roster includes Brian Liu (Director), and Leonard Post (Director). Learn More on CG Oncology's active insiders.
Are insiders buying or selling shares of CG Oncology?: In the last year, CG Oncology insiders bought shares 1 times. They purchased a total of 1,515,151 shares worth more than $49,999,983.00. In the last year, insiders at the sold shares 13 times. They sold a total of 879,359 shares worth more than $25,269,633.75. The most recent insider tranaction occured on November, 17th when Director Leonard E Post sold 1,000 shares worth more than $41,430.00. Learn More about insider trades at CG Oncology.
Information on this page was last updated on 11/17/2025.

Brian Guan-Chyun Liu Insider Trading History at CG Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/11/2025	Buy	1,515,151	$33.00	$49,999,983.00	1,515,151

Brian Guan-Chyun Liu Buying and Selling Activity at CG Oncology

CG Oncology Company Overview

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Today's Range

Now: $43.30

$43.02

$46.01

50 Day Range

MA: $41.80

$37.76

$45.51

2 Week Range

Now: $43.30

$14.80

$46.01

Volume

744,809 shs

Average Volume

848,795 shs

Market Capitalization

$3.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29